Page last updated: 2024-08-21

arsenic trioxide and Cholera Infantum

arsenic trioxide has been researched along with Cholera Infantum in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (25.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	2 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bradley, TP; Budman, DR; Kritharis, A	1
Bazarbachi, A; de Thé, H; El Hajj, H; Farid, R; Hatoum, H; Hermine, O; Kchour, G; Kooshyar, MM; Mahmoudi, M; Maleki, M; Rafatpanah, H; Rahimi, H; Rezaee, SA; Shirdel, A; Tarhini, M; Wattel, E; Yazdi, MT	1
Bowen, D; Burnett, AK; Cahalin, P; Craig, J; Hills, RK; Hunter, A; Kell, J; McMullin, MF; Milligan, D; Russell, N; Wheatley, K; Yin, J	1
Warrell, RP	1

Reviews

2 review(s) available for arsenic trioxide and Cholera Infantum

Article	Year
The evolving use of arsenic in pharmacotherapy of malignant disease. Annals of hematology, 2013, Volume: 92, Issue:6 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Biotransformation; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Gastrointestinal Diseases; Gene Expression Regulation; Heart Diseases; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Metabolic Networks and Pathways; Methyltransferases; Neoplasms; Oxides; Reactive Oxygen Species; Signal Transduction; Treatment Outcome	2013
Arsenicals and inhibitors of histone deacetylase as anticancer therapy. Haematologica, 1999, Volume: 84 Suppl EHA-4 Topics: Acetylation; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; China; Chromatin; Drug Evaluation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gastrointestinal Diseases; Histone Deacetylase Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Melarsoprol; Neoplasm Proteins; Neoplasms; Nervous System Diseases; Oxides; Phenylbutyrates; Protein Processing, Post-Translational; Salvage Therapy; Tretinoin	1999

Article

Year

The evolving use of arsenic in pharmacotherapy of malignant disease.

Annals of hematology, 2013, Volume: 92, Issue:6

Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Biotransformation; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Gastrointestinal Diseases; Gene Expression Regulation; Heart Diseases; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Metabolic Networks and Pathways; Methyltransferases; Neoplasms; Oxides; Reactive Oxygen Species; Signal Transduction; Treatment Outcome

2013

Arsenicals and inhibitors of histone deacetylase as anticancer therapy.

Haematologica, 1999, Volume: 84 Suppl EHA-4

Topics: Acetylation; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; China; Chromatin; Drug Evaluation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gastrointestinal Diseases; Histone Deacetylase Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Melarsoprol; Neoplasm Proteins; Neoplasms; Nervous System Diseases; Oxides; Phenylbutyrates; Protein Processing, Post-Translational; Salvage Therapy; Tretinoin

1999

Trials

2 trial(s) available for arsenic trioxide and Cholera Infantum

Article	Year
Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). Blood, 2009, Jun-25, Volume: 113, Issue:26 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Chemical and Drug Induced Liver Injury; Drug Eruptions; Drug Synergism; Female; Gastrointestinal Diseases; Hematologic Diseases; Human T-lymphotropic virus 1; Humans; Interferon-alpha; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Oxides; Proviruses; Remission Induction; Viral Load; Zidovudine	2009
The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome. Leukemia, 2011, Volume: 25, Issue:7 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Chemical and Drug Induced Liver Injury; Comorbidity; Cytarabine; Disease-Free Survival; Early Termination of Clinical Trials; Female; Gastrointestinal Diseases; Heart Diseases; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Oxides; Remission Induction; Treatment Outcome	2011

Article

Year

Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL).

Blood, 2009, Jun-25, Volume: 113, Issue:26

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Chemical and Drug Induced Liver Injury; Drug Eruptions; Drug Synergism; Female; Gastrointestinal Diseases; Hematologic Diseases; Human T-lymphotropic virus 1; Humans; Interferon-alpha; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Oxides; Proviruses; Remission Induction; Viral Load; Zidovudine

2009

The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome.

Leukemia, 2011, Volume: 25, Issue:7

Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Chemical and Drug Induced Liver Injury; Comorbidity; Cytarabine; Disease-Free Survival; Early Termination of Clinical Trials; Female; Gastrointestinal Diseases; Heart Diseases; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Oxides; Remission Induction; Treatment Outcome

2011